Citadel Advisors’s Clearmind Medicine CMND Stock Holding History

Citadel Advisors’s Portfolio CMND Stock Details CMND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$25.8K	Buy	+11,710	New	+$66.6K	﹤0.01%	13345
2025 Q1	–	Sell	-95	Closed	-$52.7K	–	14593
2024 Q4	$52.7K	Buy	95 +51	+116%	+$28.3K	﹤0.01%	12344
2024 Q3	$21.6K	Buy	+44	New	+$25K	﹤0.01%	12720
2023 Q4	–	Sell	-1	Closed	-$2.35K	–	14351
2023 Q3	$2.35K	Sell	1 -2	-67%	-$9.16K	﹤0.01%	13732
2023 Q2	$17.4K	Buy	3 +2	+200%	+$13.5K	﹤0.01%	12848
2023 Q1	$13.1K	Buy	+1	New	+$41.7K	﹤0.01%	13378

Other funds holding CMND

HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return

AdvisorShares Investments Bethesda, Maryland $828M AUM 37.72% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

CIAM

Caitong International Asset Management Hong Kong $729M AUM 1,176.98% 1-Year Est. Return

Citadel Advisors's CMND Position: Q2 2026 in Review

Citadel Advisors opened a new position in Clearmind Medicine (CMND) in Q2 2026: 11,710 shares worth $25.8K. The stake represents ﹤0.01% of the portfolio and ranks #13345 among its holdings. This is a return to the name: Citadel Advisors previously reported a position in CMND as recently as Q4 2024.

Citadel Advisors first reported a position in CMND in Q1 2023 and has held it in 6 quarters since. The position peaked at $52.7K in Q4 2024. 6 funds tracked by Wall St. Rank hold CMND as of Q2 2026.

Citadel Advisors held 11,710 shares of Clearmind Medicine worth $25.8K as of Q2 2026.
Clearmind Medicine was a new Citadel Advisors position in Q2 2026.
Clearmind Medicine made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #13345 holding.
Citadel Advisors first reported a position in Clearmind Medicine in Q1 2023 and has held it in 6 quarters since.
Citadel Advisors's Clearmind Medicine position peaked at $52.7K in Q4 2024.
6 funds tracked by Wall St. Rank held Clearmind Medicine as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.